Oscar Health is valued at less than 1x trailing sales, a wild valuation for a business still growing at its pace. It generated $11 billion of revenue last year and trades at a market cap of roughly $9 billion. x.com 

Oscar Health's CEO bought $12 million of stock near the lows, an eight-figure insider buy worth paying attention to. Shares are now at 5.5-year highs and close to threatening the all-time high set at the IPO price. x.com 

Oscar Health looks too extended after its big move and should pull back around earnings in the next few days; it is not a tech stock with a niche product capable of parabolic moves. x.com 

Oscar Health's drop below $30 makes little sense after it crushed Q2, swung to a profit and raised full-year operating earnings guidance. Revenue was $4.90B versus $4.75B expected and EPS $1.10 versus $0.39, with FY26 revenue guided to $18.9B versus $18.6B estimated. The market needs time to digest the result, and the stock should recover soon; it remains a long-term hold. x.com  x.com  x.com 

Oscar Health has the most room to run among health insurers, which are rallying after the administration announced increased Medicaid budgets. CEO Mark Bertolini bought about $12 million of shares at the lows, the first insider purchase this year, and Oscar's market cap is just $3.74B. The chart confirms it: a broken daily descending trendline, surging money flow and a volume spike. Resistance sits at $14.15-$15, and a close above $15 brings the 200-day moving average into play. x.com 

Oscar Health cannot be a great business because insurance, like banking, is uninvestable when its economics are nearly impossible to predict. One bad cycle or change in costs can wipe out margins that are already nonexistent. A post the author replies to argues Oscar avoided the 30-40% member drop the market expected after enhanced premium tax credits expired. x.com 

Oscar Health has already priced in the CMS crackdown while it keeps disrupting medical insurance, with 90% average annual sales growth over the past five years. The stock is not far from testing new highs since its IPO, and the price target is 42+. x.com 

Oscar Health's scale is finally producing real operating leverage as its medical loss ratio improves, undercutting the view that it is uninvestable. Q1 revenue rose 53% to $4.65 billion, operating earnings 137% to $704 million, net income 147% to $679 million and basic EPS 107% to $2.28. x.com 

Oscar Health is too hard to invest in given the state of the ACA, uncertainty over how much ICHRA can add and uncertain risk-adjustment liabilities. A full-year medical loss ratio below 80% would force rebates, though Oscar can still cut its expense ratio. Democrats winning at least partially in the midterms could bring more favorable terms for Oscar later. x.com 

Oscar Health has turned the corner and is on the verge of a dramatic profitability inflection, yet trades at under 15x free cash flow. It projects $800 million in earnings from operations, a 1,000-basis-point improvement in its medical loss ratio and over $350 million of free cash flow this year, with more than $4.5 billion of net cash. The stock is headed to $30 by the end of 2026, after a painful year in which the call did not deliver. x.com